Phase Ii study of methyl-GAG in the treatment of esophageal carcinoma
Kelsen, D.; Chapman, R.; Bains, M.; Heelan, R.; Dukeman, M.; Golbey, R.
Cancer Treatment Reports 66(6): 1427-1429
1982
ISSN/ISBN: 0361-5960 PMID: 7083245 Document Number: 190836
Twenty-four patients with epidermoid carcinoma of the esophagus have been treated, in a phase II trial, with methyl-GAG using a weekly schedule. Eighteen patients had received prior chemotherapy with cisplatin-containing combinations. Of 23 evaluable patients, four (17%) had partial remissions, each lasting 2 months. All patients had received prior chemotherapy. Toxic effects were manageable and included mild nausea and vomiting, mucositis, and fatigue. Using this schedule, methyl-GAG had modest activity in esophageal cancer, with acceptable toxicity. Its role in combination chemotherapy remains to be defined.